Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Martin Brenner
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Beta
- 1.29
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -2.04
Financials
Revenue
$0.00-100.0%Net Income
$-10.60MEBITDA
$-10.78MFree Cash Flow
$-6.25MEPS (diluted)
$-0.06Shares Outstanding (diluted)
104.06M+583817.8%Operating Expenses
$6.38MCash & Debt
$88.04MReturn of Capital
$0.00Revenue by Segment (annual)
$100.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $100.0K | $-33.04M | $-0.32 |
| 2025 | $400.0K | $-18.38M | $-1.75 |
| 2024 | $225.0K | $-24.91M | $-6.50 |
| 2023 | $0.00 | $-65.01M | $-106.18 |
| 2022 | $1.88M | $-50.39M | $-2889.06 |
| 2021 | $2.37M | $-23.21M | $-59.98 |
| 2020 | $1.64M | $-16.44M | $-304.64 |
| 2019 | $2.02M | $-17.59M | $-471.65 |
| 2018 | $444.0K | $-16.11M | $-770.00 |
| 2017 | $394.0K | $-14.53M | $-800.00 |
| 2016 | $948.0K | $-9.76M | $-600.00 |
| 2015 | $1.85M | $-6.63M | $-450.00 |
| 2014 | $205.0K | $-3.67M | $-300.00 |
| 2013 | $1.01M | $-6.20M | $-650.00 |
Valuation
IBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110-4.35%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·3d ago·Positive
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human trials of IBIO-610 in first half of 2027 SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing lon…
View source ↗ - Newsglobenewswire.com·45d ago·Positive
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston.
View source ↗ - Newsglobenewswire.com·49d ago·Positive
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress. “Fiscal year 2026 was a transformative year for iBio, most importantly marked b…
View source ↗
Earnings
Wed, Nov 11(in 4 weeks)
Consensus estimate $-0.07 per share
Typical surprise -12.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 28$-0.04 vs $-0.07beat
- Tue, May 12$-0.07 vs $-0.06miss
- Tue, Feb 10$-0.09 vs $-0.08miss
- Wed, Nov 12$-0.11 vs $-0.07miss
- Fri, Sep 5$-0.31 vs $-0.39beat
- Fri, May 2$-0.49 vs $-0.39miss
Estimates and results for IBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IBIO officers and directors.
- Bought
- $753k
- Sold
- $100k
11 trades
17 trades
- Banjak Marcbought
- Banjak Marcbought
- Duran Felipebought
- Brenner Martinbought
- Duran Felipebought
- Brenner Martinbought
- Banjak Marcbought
- Arkowitz Davidbought
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IBIO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.